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Katherine S Ong1*, Rob Carter2, Margaret Kelaher1 and Ian Anderson3Abstract
Background: Health economics is increasingly used to inform resource allocation decision-making, however, there
is comparatively little evidence relevant to minority groups. In part, this is due to lack of cost and effectiveness data
specific to these groups upon which economic evaluations can be based. Consequently, resource allocation
decisions often rely on mainstream evidence which may not be representative, resulting in inequitable funding
decisions. This paper describes a method to overcome this deficiency for Australia’s Indigenous population. A
template has been developed which can adapt mainstream health intervention data to the Indigenous setting.
Methods: The ‘Indigenous Health Service Delivery Template’ has been constructed using mixed methods, which
include literature review, stakeholder discussions and key informant interviews. The template quantifies the
differences in intervention delivery between best practice primary health care for the Indigenous population via
Aboriginal Community Controlled Health Services (ACCHSs), and mainstream general practitioner (GP) practices.
Differences in costs and outcomes have been identified, measured and valued. This template can then be used to
adapt mainstream health intervention data to allow its economic evaluation as if delivered from an ACCHS.
Results: The template indicates that more resources are required in the delivery of health interventions via ACCHSs,
due to their comprehensive nature. As a result, the costs of such interventions are greater, however this is
accompanied by greater benefits due to improved health service access. In the example case of the polypill
intervention, 58% more costs were involved in delivery via ACCHSs, with 50% more benefits. Cost-effectiveness
ratios were also altered accordingly.
Conclusions: The Indigenous Health Service Delivery Template reveals significant differences in the way health
interventions are delivered from ACCHSs compared to mainstream GP practices. It is important that these
differences are included in the conduct of economic evaluations to ensure results are relevant to Indigenous
Australians. Similar techniques would be generalisable to other disadvantaged minority populations. This will allow
resource allocation decision-makers access to economic evidence that more accurately represents the needs and
context of disadvantaged groups, which is particularly important if addressing health inequities is a stated goal.
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With growing health expenditures and greater scrutiny
of health care spending, the results of economic evalua-
tions are increasingly used to assist decisions about
health care resource allocation [1]. Economic evaluations
assist decision-makers to determine which health inter-
ventions represent the best ‘value for money’ in terms of
maximizing the health of the population with the avail-
able funds.
Such economic evidence is valuable, particularly for
groups who experience health disadvantage such as
Australia’s Aboriginal and Torres Strait Islander (or Indi-
genous) population, to indicate where resources are best
placed to help bridge the health gap. Australia’s Indigen-
ous population has a health status much worse than that
of the general Australian population, with life expectancy
10 years below that of non-Indigenous Australians [2],
and standardized morality and infant mortality rates more
than twice as high [3]. This poorer health is grounded in
complex historical, geographic, economic and socio-
cultural factors, in many ways similar to those faced by
colonized indigenous peoples worldwide. The available
evidence suggests that mainstream primary health care
services have struggled to deal with these issues and im-
prove the Indigenous health discrepancy, and that popula-
tion specific services are warranted [4-7].
It is generally accepted within Australian policy dis-
course that greater resources are necessary to improve In-
digenous health [4,8,9]. Qualitative evidence suggests that
‘best practice’ primary health care for the Indigenous
population is based on self-determination and community
control, epitomized by the Aboriginal Community Con-
trolled Health Service (ACCHS) model of comprehensive
primary health care [10-12]. An ACCHS is defined as
being an incorporated Aboriginal organization, initiated
and based in a local Aboriginal community, governed by a
locally elected Aboriginal body, and delivering a holistic
and culturally appropriate health service to the commu-
nity that controls it [13]. Community control is a central
component of this model; in other words, the health ser-
vice is run by Aboriginal people, for Aboriginal people.
Based on the premise of providing ‘equity of access’,
ACCHSs have been found to provide equitable and more
effective primary health care for the Indigenous popula-
tion [11]. However, the funding of ACCHSs remains frag-
mented and is generally considered insufficient to meet
the greater health need [14].
The results of economic evaluations could help determine
the best use of resources to improve Indigenous health.
However, such evidence specific to the Indigenous context
remains deficient. In part, this can be explained because eco-
nomic evaluation techniques depend on modeling from
existing quantitative data, to determine both the total costs
of a health intervention, and to extrapolate to improvementsin health effect or benefit [15]. Due to the relatively small
size of Australia’s Indigenous population, there is a lack of
cost and effectiveness data specifically pertaining to this
group that takes into account their unique demographic fea-
tures, socio-cultural context, and preferred health service
models. Therefore, there is a corresponding lack of Indigen-
ous specific health economics data. This means that re-
source allocation decisions for Indigenous health are often
based on mainstream economic evidence which may not be
representative, or not based on economic evidence at all.
Under these circumstances cost-effectiveness results may be
distorted, and health inequalities may in fact be perpetuated
rather than improved.
This paper describes one method by which this deficiency
in Indigenous health economics data could be overcome.
The ‘Indigenous Health Service Delivery (IHSD) Template’
has been developed, which quantifies the differences in how
health interventions are delivered to the Indigenous popula-
tion via ACCHSs compared to mainstream general practi-
tioner (GP) based services, the latter being the standard
form of primary health care available in Australia. Differ-
ences in costs and benefits have been identified, measured
and valued in the construction of the template. The IHSD
Template can then be applied to adapt mainstream data, to
allow its economic evaluation as if interventions were deliv-
ered to the Indigenous population via best practice methods
of health service delivery. Therefore, economic evaluation
results which are based on mainstream evidence can be
made more relevant to the Indigenous context and facilitate
more meaningful resource allocation recommendations.
An additional advantage of the IHSD Template is
that it provides a measure of equitable health service
provision, in terms of the additional costs incurred and
the improved health benefits that result. Therefore, it is
an important potential tool for decision-makers when
achieving health equity is a pressing policy imperative, in
an area where, to date, quantitative data has been
limited.
The research outlined in this paper comprised part of
the larger Assessing Cost Effectiveness in Prevention
(ACE-Prevention) project, which evaluated the cost-
effectiveness of interventions to prevent chronic disease
in the Australian population [16]. As part of this study,
separate economic evaluations were performed for the
general (or total) Australian population and for the Indi-
genous Australian population. Separate evaluations were
necessary to account for differences in demographics,
the target disease burden, the prevalence and distribu-
tion of harmful exposures, the way health interventions
are delivered, and their effectiveness. The content of this
paper draws on the Indigenous component of the ACE-
Prevention project, and expands on information con-
tained within the ACE-Prevention final report and dis-
semination pamphlets [16,17].
Ong et al. BMC Health Services Research 2012, 12:307 Page 3 of 11
http://www.biomedcentral.com/1472-6963/12/307Methods
Mixed methods were used in the development of the
IHSD Template. Data was sought to identify, measure and
value the differences in how primary health care interven-
tions are delivered between ACCHSs compared to main-
stream GP services. Information was initially obtained
from a general search of the publicly available literature.
Searches were made of PubMed and Web of Science,
along with the grey literature and discussion with experts
in the field. This search only revealed a small number of
studies, none of which provided sufficient quantitative in-
formation for use in economic evaluation [18,19]. Aggre-
gated government data was available on levels of ACCHS
service provision in the form of the Service Activity
Reports [20], however no cost information was provided.
Using the data gathered from the literature, a base IHSD
Template was constructed.
Following the literature search, further information
and validation of the data gathered was sought from the
ACE-Prevention Indigenous Steering Committee (ISC),
which consisted of academics and policy makers selected
to represent a broad range of expertise in Indigenous
health. Three key meetings were held between 2006 and
2009, during which the base IHSD Template was dis-
cussed, and feedback used to identify additional sources
of information and improve the template structure.
In addition, key informant interviews were conducted
with people working within the ACCHS sector. Sixteen
interviews with staff of varying roles from a range of
ACCHSs in different remoteness localities took place be-
tween July and November 2008 (Table 1). In total, staff
from 5 different health services were represented.
Informed consent was obtained in all cases and prior to
the interview, a plain language summary of the IHSD
Template and its structure was provided. This was fol-
lowed by an interview using a standardized, semi-
structured open-ended interview schedule that consisted
of opinion and knowledge questions about how well the
IHSD Template reflected real life work practices. In par-
ticular, the questionnaire was designed to validate the
base IHSD Template that had been derived from the lit-
erature, and to obtain quantitative estimates of certain
parameters that were not able to be found elsewhere.
Ethics approval was obtained from the Human ResearchTable 1 Summary of key informant characteristics
Health service location Total no. key inform
Urban – Melbourne 7
Rural - Victoria 1
Remote – Central Australia and Northern Territory 8
Total 16
AHW=Aboriginal Health Worker.Ethics Committees of the University of Melbourne and
Central Australia (via the Menzies School of Health Re-
search). Subject recruitment was by snowball methods
with initial identification made by research contacts
within Indigenous health. The management of the
ACCHSs were approached for initial permission to con-
duct the interviews, and feedback was in the form of a
community report and dissemination of other project
reports and publications [17].
Interviews were de-identified prior to analysis, and
incorporated along with feedback from the ISC meetings
and data from the literature to validate and further re-
fine the template. Specifically, general comments regard-
ing the IHSD Template were incorporated where
possible. Responses to the quantitative questions were
collated in a crude manner as estimates and used as
inputs for the template where alternative data was not
available. Ranges were used where relevant to reflect the
diversity of key informant responses. Specific parameters
for which information from the interviews was used are
detailed in Additional File 1.
The IHSD Template describes differences in the con-
duct of standard patient consultations between ACCHSs
and mainstream GP practices in terms of their costs and
impact on treatment effects. In keeping with the terms
of reference for the ACE-Prevention project, a health
sector perspective has been taken, and all costs mea-
sured in Australian dollars and referenced to the year
2003 [21]. IHSD Template values have been calculated
for remote area, non-remote area, and national average
decision contexts, to account for regional differences in
costs and service provision. The mainstream GP com-
parator is based on the provision in non-remote services,
due to the relatively small proportion of non-Indigenous
Australians who live in remote areas and the corre-
sponding lack of remote mainstream GP practices.
Use of the IHSD Template has been trialled in several
economic evaluations of interventions to prevent either car-
diovascular disease, diabetes or chronic kidney disease in the
Australian Indigenous population as part of the ACE-
Prevention project [16]. This has involved the adaptation of
disease-specific epidemiological models to ensure data is
relevant to the Indigenous population. In this paper, the
‘Cardiovascular Disease Prevention Model’ has been usedants Position within health service
Manager Medical Nursing AHW Other
3 2 2
1
1 4 2 1
4 7 2 2 1
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developed by Stephen Lim for the ACE-Heart disease
project and subsequently used in the ACE-Prevention
project [22-24]. This model is a Markov model developed in
Microsoft Excel (Microsoft Corporation, Washington, USA)
which uses the modified disability-adjusted life-year (DALY)
as the measurement of health benefit [1]. The Cardiovascu-
lar Disease Prevention Model has been adapted to the
Indigenous population as the ‘Indigenous Cardiovascular
Disease Prevention Model’ by the author (KO, unpublished)
to account for differences in the Indigenous burden of
disease and demographic factors.
Results
Identification of IHSD Template components
Using the data collection methods described, a frame-
work of ‘components’ have been identified which de-
scribe how health interventions delivered from ACCHSs
differ from those delivered from mainstream GP services
(Table 2). Health service definitions were taken from the
National Aboriginal Health Strategy [11] for ACCHSs
and the Royal Australian College of General Practi-
tioners [25] for GP services. The IHSD Template com-
ponents are grouped into six broad categories as listed
below (reproduced from Vos et al. [16] and Ong [17]):
Basic health intervention delivery characteristics:
 Role substitution – a patient may be seen by an
Aboriginal Health Worker or a nurse in addition to,
or instead of, a doctor
 Compliance management – e.g. medication dosing
and appointment recalls
 Staff training activities – e.g. cultural in addition to
professional training for non-Indigenous staff
 Emphasis on home visits
 Time spent on paperwork, case conferencing and
the management of complex medical conditions
 Seeing of other family members as part of routine
consultationsTable 2 The additional cost of IHSD Template
components (averaged across total Indigenous
population) (Reproduced from Ong [17])
IHSD Template component
category
Additional cost per ACCHS patient
encounter
Basic health intervention delivery
characteristics
$16.67-$31.57 (depending on
consultation length)
Population health, social and
community activities
$9.28
Management and governance $3.87
Patient transport services $47.01
Services to remote regions $5.50Population health, social and community activities:
 Provision of other services – e.g. social work and
counseling
 Provision of services usually provided by outside
agencies – e.g. pharmacy, financial and housing
assistance
 Health promotion and community development
activities
 Provision of a community space
Management and governance structures:
 Presence of a community management board and
the associated need for community capacity building
in management
 Additional management resources required for
overseeing larger staff numbers and multiple
projects
Patient transport services:
 Provision of transport for patients to and from
appointments
Provision of services to a large remote population:
 Out of hours emergency care
 Outreach services
 Housing and relocation costs for staff
 Additional costs associated with pharmaceutical and
pathology services
Differences in rates of Indigenous utilization of ser-
vices and adherence to treatments:
 Differences in rates when interventions are delivered
from ACCHSs compared to mainstream GP clinics
due to improved access
Measurement and valuation of IHSD Template
components
Differences in the quantity or magnitude of the IHSD
Template components listed above (between ACCHSs
and mainstream GP services) have been estimated based
on the same sources of information outlined in the
methods section. Where relevant, the components have
also been valued in terms of cost. Total costs have then
been calculated by multiplying the quantity of the com-
ponent by its unit cost. Average additional costs are
attributed to a single ‘encounter’ (standard consultation)
with a health care practitioner at an ACCHS (Table 2).
This then allows intervention costs to be adjusted
according to the number of health practitioner visits that
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Therefore, additional costs of intervention delivery via
ACCHSs are allocated as a form of joint cost (analogous
to overhead costs) proportional to its health service
requirements.
The component costs are totalled and presented in
Table 3 as the ‘IHSD Template values’, along with the
differences in rates of Indigenous utilization of health
services, adherence to treatments, and the ratio of differ-
ences in future cost-offsets. Subgroup analysis has also
been performed according to whether ACCHSs are
located in remote or non-remote areas, and these results
are also shown in Table 3. Further details of the data
sources used in generating these values are available as
Additional file 1.
Uncertainty analysis has been included to account for
uncertainty in the input parameters. A range of IHSD
Template values have been generated by means of
Monte Carlo simulation (2000 iterations) using the Excel
add in software @Risk (Palisade Corporation, New York,
USA), and this is displayed as uncertainty ranges in
Table 3. These IHSD Template values can subsequently
be used to adapt mainstream evidence for use in the
economic evaluation of interventions from Indigenous
settings.
Use of the IHSD Template values in an example
Prior to discussing the IHSD Template, its use is best illu-
strated in an example economic evaluation. The interven-
tion is the hypothetical application of a ‘polypill’ medication
(comprising an angiotensin converting enzyme inhibitor, a
beta-blocker, a calcium channel blocker, and a statin) in the
prevention of cardiovascular disease (CVD). This interven-
tion was selected as it has been flagged as an intervention of
potentially significant benefit for the Indigenous population,
and may assist in narrowing the health gap [26-28]. This
intervention was evaluated as part of the ACE-Prevention
project, however although the original intervention was spe-
cified for evaluation from mainstream GP settings, no spe-
cific data was available for its delivery via ACCHSs.
In this example, the two alternative target populations
are the total general Australian population, and total In-
digenous Australian population. In both cases, the inter-
vention is applied to those aged 55 years and above, an
age group considered to be at higher cardiovascular risk.
For simplicity, differences according to remoteness have
not been included. As this medication remains experi-
mental, a hypothetical cost of AUD $500 per annum has
been applied. This cost was the upper limit of a range
considered reasonable by experts in the field for the cost
of such a preparation [personal communication]. The
upper limit was selected for this example as lower drug
costs result in dominance of the intervention (health
gain with cost-savings) when delivered from mainstreamGP practices. Subsequently, when subject to economic
evaluation the cost-effectiveness ratio is negative. The mag-
nitude of negative cost-effectiveness ratios cannot be mean-
ingfully compared across interventions, and thus is less
informative as an example in this case. The intervention is
evaluated as being delivered to the general Australian popu-
lation via mainstream GP practices, and for the Indigenous
population, has been evaluated as if delivered either via
mainstream GP practices or ACCHSs (using the IHSD
Template from Table 3).
The values of the different intervention parameters are
shown in Table 4. The biological effectiveness of the
intervention is assumed to be the same for both the gen-
eral Australian and Indigenous populations (taken from
the multiplicative effects of the component drugs from
several studies [29-31]). It can be seen from Table 4 that
intervention costs are the same if delivered via main-
stream GP practices to both the general Australian and
Indigenous populations, however there are differences in
the utilization and treatment adherence rates, and cost-
offsets between the two groups. If the intervention is
delivered to the Indigenous population via ACCHSs,
then the costs of the intervention are increased in line
with the IHSD Template values while utilization and
treatment adherence rates are also increased accordingly.
An assumption has been made that 65% of eligible GPs
participate in any particular intervention.
The values obtained in Table 4 were inputted into the
relevant decision-analytic epidemiological models (modeling
the prevention of CVD in either the general Australian or
Indigenous populations) to perform the economic evalua-
tions. The results of these evaluations are shown in Table 5.
The results in this example reveal that the cost-
effectiveness ratio is lowest for the intervention applied
to the general Australian population via mainstream GP
practices, and highest for the Indigenous population
when delivered via ACCHSs. The smaller absolute num-
ber of DALYs saved and net costs for the Indigenous
population are primarily due to the relatively smaller
population size, but also reflect lower utilization and ad-
herence rates compared to the general Australian popu-
lation. Improved access for the Indigenous population
results in a greater number of DALYs saved when the
intervention is delivered via ACCHSs compared to
mainstream GP practices, however the higher costs of
running these services is reflected in greater net costs.
The significance of these results is considered in the fol-
lowing discussion.
Discussion
The Indigenous Health Service Delivery Template
described in this paper provides a mechanism by which
intervention data obtained from mainstream sources can
be adapted to allow its economic evaluation as if
Table 3 IHSD Template values for total Indigenous population (including 95% uncertainty ranges)
IHSD Template value Mainstream GP
services (95% uncertainty)
ACCHS (95% uncertainty)
Total indigenous pop Non-remote indigenous pop Remote indigenous pop
Short consultation cost $ 30.85 $ 113.18
($78.74–$149.43)
$ 91.21 ($59.93–$127.80) $ 168.36 ($104.00–$235.42)
Long consultation cost $ 58.55 $ 155.78
($101.76–$220.13)
$ 129.34 ($76.99–$187.94) $ 223.42 ($134.49–$319.30)
Pathology test adjustment
ratio
1 1.16 (1.13–1.18) 1 1.60 (1.51–1.69)
Indigenous utilization rate
(cf. non-Indigenous)
60.0% (50.8%–69.6%) 73.2%
(63.0%–82.6%)
As for total Indigenous pop* As for total Indigenous pop*
Indigenous adherence rate
(cf. non-Indigenous)
77.8% (65.7%–89.7%) 95.7% (83.5%–108.3%) As for total Indigenous pop* As for total Indigenous pop*
Cost-offsets ratio
(Indigenous : non-Indigenous)
1.19 (0.96–1.49) 1.19 (0.96–1.49) As for total Indigenous pop* As for total Indigenous pop*
* Indigenous utilization and adherence rates and cost-offsets were not assessed separately for the non-remote and remote populations, so values calculated are those for the total Indigenous population.
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Table 4 Intervention parameters for the polypill intervention (Year 1 shown only)
Intervention parameter General population Indigenous population
Mainstream GP services Mainstream GP services ACCHSs
Intervention effectiveness:
•2RR Acute coronary syndrome 0.45 0.45 0.45
•RR stroke 0.31 0.31 0.31
Intervention costs AUD$ (Yr 1):
•1 Long consultation $58.55 $58.55 $155.78*
•2 Short consultations $61.70 $61.70 $226.36*
•Medication $500.00 $500.00 $500.00
•Pathology tests $43.62 $43.62 $50.60* ($43.62 x 1.16)
Health service utilization rate 82% 49.2%* (82% x 60%) 60%* (82% x 73.2%)
Treatment adherence rate 60% 46.7%* (60% x 77.8%) 57.4%* (60% x 95.7%)
Cost offsets AUD$ (Yr 1) (savings per CVD case averted) $11,078 $13,183* ($11,078 x 1.19) $13,183* ($11,078 x 1.19)
* Indicates values for which the IHSD Template (from Table 3) has been applied (calculations in parentheses).
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Table 5 Cost-effectiveness of the polypill priced at $500 in preventing CVD
Target population Health service type DALYs saved Net costs (AUD$ millions) Cost-effectiveness ratio (AUD$/DALY)
Total Australian aged 55+ Mainstream GP practice 1000000 12000 11000
Total Indigenous aged 55+ Mainstream GP practice 550 7.2 13000
Total Indigenous aged 55+ ACCHS 830 17 21000
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specific evidence is deficient. Thereby, results are made
more relevant to the Indigenous context.
The results reveal that the cost of a health practitioner
encounter (or consultation) at an ACCHS is more ex-
pensive than a consultation at a mainstream GP practice,
due to the additional components identified as part of
providing the ACCHS model of comprehensive primary
health care (Table 3). This contributes to the greater net
costs of interventions; in the case of the polypill ex-
ample, AUD $17 million when delivered via ACCHSs
compared to $7.2 million from mainstream GP practices
(Table 5), an increase of 58%. Health service provision
from ACCHSs is also more expensive in remote regions
compared to non-remote areas due to the additional ser-
vices involved. Cost-offsets are higher for the Indigenous
population irrespective of what type of health service is
accessed due to the greater costs associated with treating
more complex disease in this population [32].
One outcome of these differing models of health care is
that health service access can be improved for Indigenous
Australians. This is illustrated by higher Indigenous rates
of utilization of health services and adherence to treat-
ments delivered from ACCHSs compared to mainstream
GP practices. Therefore the health benefits of interven-
tions are also greater, with the polypill example revealing
50% more net benefit when the intervention is delivered
from ACCHSs compared to mainstream GP practices
(830 compared to 550 DALYs saved from Table 5). Such
improvements are important in addressing health inequi-
ties and attempts to narrow the Indigenous health gap.
The overall impact of these differences in costs and effects
is that despite their greater benefits, cost-effectiveness ratios
are higher if interventions are delivered to the Indigenous
population via ACCHSs compared to mainstream GP prac-
tices (in the case of the polypill example, $21,000 per DALY
prevented compared to $13,000 per DALY prevented re-
spectively). This is because the additional costs involved in
the delivery of interventions from ACCHSs are proportion-
ally greater than the additional benefits. When analysis is
restricted to interventions delivered from mainstream GP
practices, it is more cost-effective (lower cost-effectiveness
ratio) to deliver the intervention to the general Australian
population rather than the Indigenous population (for the
polypill, $11,000 compared to $13,000 DALY/saved). This
can be attributed to differences in adherence rates between
the two populations. Similar overall results were obtained inthe economic evaluation of several other case study inter-
ventions performed as part of the ACE-Prevention project
[33]. The need to interpret these results carefully and with
reference to context is discussed in the following section.
Implications of results
From the development of the IHSD Template, it can be seen
that delivery of interventions via ACCHSs provides greater
health benefits for the Indigenous population compared to
delivery via mainstream GP practices. However, these bene-
fits require additional resources and therefore come at
greater cost. Use of the template in an example economic
evaluation has revealed a higher cost-effectiveness ratio
when an intervention is delivered to the Indigenous popula-
tion from ACCHSs compared to delivery from mainstream
GP practices. Moreover, results indicate it is more cost-
effective to apply interventions to the general Australian ra-
ther than the Indigenous population from mainstream GP
settings. However, these results require careful analysis.
It is clear that simplistic interpretation of cost-effectiveness
ratios in this case would direct resources away from
ACCHSs and the Indigenous population in general, and is
therefore unlikely to be acceptable on social justice grounds.
In light of the present Indigenous health disadvantage and
the stated Australian government policy goal of bridging the
health gap, the economic question instead becomes whether
the additional spend on Indigenous health represents a
worthwhile use of resources. In other words, is the additional
health benefit achieved with the provision of interventions
via ACCHSs worth the additional costs? The answer not
only relates to efficiency, but in the case of disadvantaged
groups, concerns for equity and social justice are often para-
mount. These considerations should be borne in mind when
assessing cost-effectiveness ratios, for example, via the appli-
cation of equity weights. It is not the intention to examine
these issues within this discussion, however the topic has
been addressed by the authors in a separate paper [34]. It is
important that these results contribute to decision-making,
but are not considered in isolation from the broader policy
factors.
Advantages of the IHSD Template
One of the main advantages of the IHSD Template is that
it provides a simple and convenient mechanism by which
the economic evaluation of interventions can be made
more relevant to the Indigenous population when Indi-
genous specific evidence is not available. Therefore
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Indigenous health, and can provide valuable evidence to
assist resource allocation decision-making within this con-
text. In addition, the IHSD Template can assist in quanti-
fying and valuing the amount of resources required to
deliver interventions equitably to the Indigenous popula-
tion using best practice mechanisms, and thereby contrib-
ute to determining funding allocations.
Limitations of the IHSD Template
Measurement and valuation of IHSD Template compo-
nents has required extrapolation from data sources which
may not precisely represent those components, and due to
resource constraints, interviews performed provided in-
formative rather than comprehensive data. Therefore, this
research should be seen as a scoping exercise in the devel-
opment of a prototype IHSD Template and is not prescrip-
tive. These results nevertheless may serve as a guide to
health service requirements, and can indicate areas where
data gaps exist and further research is required.
It is acknowledged that the method of comparing the
additional components provided in the delivery of health
interventions via ACCHSs with delivery via mainstream
GP services could be considered simplistic and to not
adequately capture the complexity and interconnected-
ness of an Indigenous health service [19]. However, in
light of the overall lack of such evidence, the IHSD
Template could be deemed an appropriate starting point
that provides improved estimates over results based
purely on mainstream evidence alone.
Other potential limitations of the technique include
that the application of additional costs associated with
ACCHSs delivery to a ‘patient encounter’ means only
interventions which include health practitioner consulta-
tions can be evaluated using the IHSD Template. In
addition, the IHSD Template is a broad generalization of
what are inherently context specific health services, al-
though some differentiation has been made for services
provided in remote and non-remote areas. The specifi-
city of the template needs to be balanced against the
amount of data required in its construction and its ease
of use in practice. Further qualitative judgements are
required as part of the decision-making process to take
these factors into account.
Implications of the IHSD Template for policy and practice
When using economic evaluation results to inform re-
source allocation decision-making, it is important that
analyses are relevant to the target populations to whom
the interventions are applied. This research has illustrated
that there can be large differences in how a particular
intervention is delivered between different health service
delivery models, and this impacts on both the costs of the
intervention and its effectiveness. As a consequence, theeconomic evaluation results for a single intervention can
differ according to the target population and health ser-
vice context in which it is delivered, and it is not appropri-
ate to assume that cost-effectiveness ratios are the same
for all population sub-groups.
The lack of intervention cost and effectiveness data for
minority disadvantaged groups, such as Australia’s Indi-
genous population, on which to base economic evalua-
tions is inevitable in light of limited research capacity
and evaluation budgets. Yet economic evidence remains
an important tool in prioritizing the need for interven-
tions aimed at improving health inequities. The IHSD
Template proposed in this paper enables evidence to be
made more relevant to the Indigenous population with-
out the need to specifically trial every intervention from
an Indigenous health service context. The method is also
generalisable to other population sub-groups who ex-
perience health disadvantage, and for whom an equitable
model of health service delivery can be identified.
On a broader scale, the results of this analysis illustrate
the potential benefits of targeted models of health service
delivery over mainstream health services in addressing
health inequities. The same interventions can produce
more health gain for Australia’s Indigenous population if
delivered from ACCHSs compared to mainstream GP ser-
vices, and thus provide a valuable mechanism in them-
selves by which the Indigenous health gap could be
addressed, irrespective of the types of interventions imple-
mented. However, these advantages come at greater cost
and additional resources are required.
These results have implications for how health services
are optimally funded. In Australia, ACCHSs tend to be
funded from multiple sources via project specific grants
[14]. However, a more appropriate alternative would be
holistic funding of these health services in recognition of
their inherent benefits as a health care delivery vehicle
(over and above the benefit of any interventions deliv-
ered from them). Via the identification, measurement
and valuation of the additional components provided as
part of ACCHS care, the IHSD Template could indicate
the amount of resources required to provide health ser-
vices equitably, and further research in this direction is
warranted. In this way, interventions could subsequently
be selected by health services which are culturally sensi-
tive and in line with their budgets and locally deter-
mined health needs.
Conclusion
This paper has described the development and application
of the Indigenous Health Service Delivery (IHSD) Tem-
plate; a tool for use in the economic evaluation of primary
health care interventions targeting the Australian Indigen-
ous population when context specific data is deficient.
The template identifies, measures and values differences
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and mainstream GP practices. This then allows interven-
tion cost and effectiveness data from mainstream to be
adapted to allow its economic evaluation is as if delivered
from an Indigenous setting. The method is simple in its
application, and reveals that more resources are required
in the provision of interventions from ACCHSs. This is
associated with greater health benefits due to improved
service access, and these changes impact on the calculated
cost-effectiveness ratios that ensue.
The approach highlights the importance of access to
context specific health economics data when assessing
interventions for disadvantaged groups. Failure to do so
may result in resource allocation decisions based on evi-
dence which is not representative, and this could per-
petuate or even exacerbate health inequities. Although
the example of Australia’s Indigenous population has
been used, the technique could be generalized to other
minority groups who experience health disadvantage and
for whom an equitable model of health service delivery
is available. This is particularly important if addressing
health inequities is a stated policy goal.
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